BIOSIMILARS SWITCH: DO DOCTORS AND PATIENTS REVERT BACK AFTER SWITCHING?
1ISG-023
CYSTIC FIBROSIS OUTPATIENT TREATMENT COSTS: A RETROSPECTIVE ANALYSIS
1ISG-022
FINANCIAL IMPACT OF THIRD-GENERATION CEPHALOSPORINES RESISTANCE IN HOSPITAL SETTINGS – AN EXAMPLE WITH CEFTRIAXONE
1ISG-021
A COMPREHENSIVE REGIONAL STRATEGY ADDRESSING GUIDANCE ON SAFE HANDLING OF HAZARDOUS DRUGS
1ISG-020
CHEMICAL RISK ASSESSEMENT IN A QUALITY CONTROL LABORATORY BY A TOOL USING ACTIVITY ANALYSIS
1ISG-019
INSIGHT INTO PHARMACY AND THERAPEUTICS COMMITTEES' STRUCTURE AND ACTIVITIES AMONG HOSPITALS IN X: MIXED-METHODS APPROACH
1ISG-018
ORGANISATIONAL COMMITMENT OF HOSPITAL PHARMACISTS, RELATING TO THE SUPPORTIVE ORGANISATIONAL ENVIRONMENT
1ISG-017
CLINICAL AND ECONOMIC EVALUATIONS OF MORPHINE AND FENTANYL WITH MECHANICAL VENTILATION IN INTENSIVE CARE SETTINGS: A SYSTEMATIC REVIEW OF METHODOLOGICAL TRENDS, AND REPORTING QUALITY
1ISG-016
COST-EFFECTIVENESS OF MORPHINE VERSUS FENTANYL IN MANAGING VENTILATED NEONATES WITH RESPIRATORY DISTRESS SYNDROME IN THE INTENSIVE CARE SETTING
1ISG-015
OPTIMISATION OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS
1ISG-014
RHEUMATOID ARTHRITIS: BIOLOGICAL DRUGS PHARMACEUTILISATION ANALISYS IN AN ITALIAN DISTRICT
1ISG-013
BUDGET IMPACT ANALYSIS OF LUNG CANCER IMMUNOTHERAPY: A HOSPITAL PERSPECTIVE
1ISG-012
COST-EFFECTIVENESS OF AZACITIDINE IN THE REAL-WORLD: ANALYSIS IN HIGH-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM THE PERSPECTIVE OF A EUROPEAN PUBLIC HOSPITAL
1ISG-011
REDUCTION OF THE PATIENT WAITING TIME: WHAT COST FOR THE CHEMOTHERAPIES PREPARATION UNIT?
